Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
351
datasets available to search
ShareScore release 0.9.0
Dataset results
351 results for “empagliflozin”
Dataset related to: Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway
<p>The files contain all the dataset included in the manuscript divided by figures.</p> <p>Abstract<br> In addition to having blood glucose-lowering effects, inhibitors of sodium glucose cotransporter 2 (SGLT2) afford renoprotection in diabetes. We sought to investigate which components of the glomerular filtration barrier could be involved in the antiproteinuric and renoprotective effects of SGLT2 inhibition in diabetes. BTBR (black and tan, brachyuric) <em>ob/ob</em> mice that develop a type 2 diabetic nephropathy received a standard diet with or without empagliflozin for 10 weeks, starting at 8 weeks of age, when animals had developed albuminuria. Empagliflozin caused marked decreases in blood glucose levels and albuminuria but did not correct glomerular hyperfiltration. The protective effect of empagliflozin against albuminuria was not due to a reduction in podocyte damage as empagliflozin did not affect the larger podocyte filtration slit pore size nor the defective expression of nephrin and nestin. Empagliflozin<br> did not reduce the thickening of the glomerular basement membrane. In BTBR <em>ob/ob</em> mice, the most profound abnormality seen using electron microscopy was in the endothelial aspect of the glomerular capillary, with significant loss of endothelial fenestrations. Remarkably, empagliflozin ameliorated the subverted microvascular endothelial ultrastructure. Caveolae and bridging diaphragms between adjacent endothelial fenestrae were seen in diabetic mice and associated with increased expression of caveolin-1 and the appearance of PV-1. These endothelial abnormalities were limited by the SGLT2 inhibitor. Although no expression of SGLT2 was found in glomerular endothelial cells, SGLT2 was expressed in the podocytes of diabetic mice. VEGF-A, which is a known stimulus for endothelial caveolin-1 and PV-1, was increased in podocytes of BTBR <em>ob/ob</em> mice and normalized by SGLT2 inhibitor treatment.<br> Thus, empagliflozin’s protective effect on the glomerular endothelium of diabetic mice could be due to a limitation of the paracrine signaling of podocyte-derived VEGF-A that resulted in a reduction of the abnormal endothelial caveolin-1 and PV-1, with the consequent preservation of glomerular endothelial function and permeability.</p>
Pharmacodynamics parameters underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
<p><b>Background</b>: Empagliflozin is an SGLT2 inhibitor approved for use in patients with Diabetes Mellitus type 2 (DMT2) with- or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed<b> </b>to determine the chronopharmacological effects of morning vs evening administration of empagliflozin 10 mg in Healthy Egyptian adults, by investigating the pharmacokinetics and pharmacodynamics parameters of empagliflozin depending on the intake time. </p> <p><b>Methods: </b>An open label, sequential, two‐way crossover trial comprised two periods with a washout period of 7 days. Pharmacokinetics parameters (t<sub>max</sub> (h), C<sub>max</sub> (ng/ml), AUC <sub>0-t</sub> (ng.h/ml)) as primary endpoints, and (AUC <sub>0 to ∞</sub>(ng.h/ml)) as secondary endpoint were assessed. Method validation was done prior to injection in LC/MS/MS and samples were processed by Liquid-Liquid extraction. The pharmacodynamic profile (UGE <sub>0-24</sub>) was determined after method validation (glucose hexokinase method).</p> <p><b>Results: </b>T<sub>max</sub> increased by (35%) in the evening phase compared to the morning phase, while C<sub>max</sub> decreased by (-6.5%)in the evening dose compared to the morning dose. Besides, AUC<sub>0 to ∞</sub> increased in the evening phase by (8.25%) compared to the morning phase. The mean cumulative amount of glucose excreted; UGE (<sub>0-24</sub>) increased by (43%) in the evening dose compared to the morning dose</p> <p><strong>Conclusion: </strong>Despite there was a significant difference between morning and evening doses, it didn't reach the significant level, thus, it can be concluded that there is no difference between the morning and evening doses.</p>
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01276288. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon
ClinicalTrials.gov study NCT01328184. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
ClinicalTrials.gov study NCT01422876. IPD Sharing: Not stated. Countries: 22. Publications: 3.
Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Giv
ClinicalTrials.gov study NCT01301742. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01581658. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance an
ClinicalTrials.gov study NCT01248364. IPD Sharing: Not stated. Countries: 3. Publications: 3.
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01159600. IPD Sharing: Not stated. Countries: 12. Publications: 5.
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chron
ClinicalTrials.gov study NCT05254002. IPD Sharing: NO. Countries: 14. Publications: 7.
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT02863328. IPD Sharing: Not stated. Countries: 12. Publications: 8.
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
ClinicalTrials.gov study NCT03429543. IPD Sharing: YES. Countries: 14. Publications: 1.
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
ClinicalTrials.gov study NCT02589626. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01177813. IPD Sharing: Not stated. Countries: 9. Publications: 4.
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01167881. IPD Sharing: Not stated. Countries: 23. Publications: 5.
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
ClinicalTrials.gov study NCT03087773. IPD Sharing: NO. Countries: 1. Publications: 9.
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT02589639. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
ClinicalTrials.gov study NCT03462069. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
ClinicalTrials.gov study NCT03332212. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
ClinicalTrials.gov study NCT01778049. IPD Sharing: Not stated. Countries: 11. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.